Purpose of the study:~Study of the effectiveness and safety of the drug Mefloquine, tablets 250 mg, produced by FSUE SPC farmzaschita  FMBA of Russia (Russia), in comparison with the drug Hydroxychloroquine, tablets 200 mg, for the treatment of patients with coronavirus infection, in the off-label mode, to make a decision on the possibility of expanding the indications for use.~Study aims:~To study the efficacy of the drug Mefloquine, tablet 250 mg, for the treatment of patients with coronavirus infection (light and medium-heavy form), the appointment in the off-label in comparison with the drug Hydroxychloroquine tablets 200 mg, when administered in the mode off label.~To study the effectiveness of the drug Mefloquine, tablet 250 mg, when administered in the mode off label, in comparison with the drug Hydroxychloroquine tablets 200 mg, when administered in the mode off label when applied to a schema for the treatment of patients with severe coronavirus infection.~Evaluate the safety and tolerability of Mefloquine, 250 mg tablets, and Hydroxychloroquine, 200 mg tablets, for the treatment of patients with coronavirus infection (mild and moderate-severe forms).~Evaluate the safety and tolerability of Mefloquine, 250 mg tablets, and Hydroxychloroquine, 200 mg tablets, for the treatment of patients with coronavirus infection (severe forms), when used as part of a regimen for the treatment of patients with severe coronavirus infection.~Study design:~An open, randomized, multicenter comparative study of the efficacy and safety of Mefloquine and Hydroxychloroquine in off-label mode for the treatment of patients with COVID-19 coronavirus infection
Study of the effectiveness and safety of the drug Mefloquine, tablets 250 mg, produced by FSUE SPC Farmzaschita  FMBA of Russia (Russia), in comparison with the drug Hydroxychloroquine, tablets 200 mg, for the treatment of patients with coronavirus infection, in the off-label mode, to make a decision on the possibility of expanding the indications for use.